Dhananjai Shrivastava

Title: Dhananjai Shrivastava: Innovator in HIV Integrase Inhibitors

Introduction

Dhananjai Shrivastava is a notable inventor based in Pune, India. He has made significant contributions to the field of pharmaceuticals, particularly in the development of HIV integrase inhibitors. With a total of 3 patents to his name, his work has the potential to impact the treatment of HIV.

Latest Patents

Dhananjai's latest patents include a process for the preparation of intermediates used for the synthesis of HIV integrase inhibitors. This process is crucial for the development of drugs such as Bictegravir, Dolutegravir, and Cabotegravir, along with their pharmaceutically acceptable salts. Another significant patent he holds is related to the preparation of a compound of formula (XVII), which involves various alkyl groups and hydroxyl protecting groups, showcasing his innovative approach to drug synthesis.

Career Highlights

Dhananjai works at Lupin, Inc., a prominent pharmaceutical company known for its commitment to healthcare innovation. His role at Lupin has allowed him to focus on research and development in the field of HIV treatment, contributing to the advancement of medical science.

Collaborations

Throughout his career, Dhananjai has collaborated with talented individuals such as Girij Pal Singh and Harishchandra Sambhaji Jadhav. These collaborations have fostered a creative environment that encourages innovation and the development of new pharmaceutical solutions.

Conclusion

Dhananjai Shrivastava's work in the field of HIV integrase inhibitors exemplifies the importance of innovation in pharmaceuticals. His contributions are paving the way for more effective treatments for HIV, showcasing the impact of dedicated inventors in the medical field.